๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

โœ Scribed by Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A. Eden Evins; David C. Henderson; Corinne Cather; Donald C. Goff

Publisher
Springer
Year
2005
Tongue
English
Weight
107 KB
Volume
181
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A double-blind, placebo-controlled trial
A double-blind, placebo-controlled trial
โœ Robert S. Pinals; Stanley B. Kaplan; Jeffrey G. Lawson; Bonnie Hepburn ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 663 KB
Tolcapone added to levodopa in stable pa
Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study
โœ Dr. Erik Dupont; Jean-Marc Burgunder; Leslie J. Findley; Jan-Edvin Olsson; Ernes ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 601 KB

The primary objective of this study was to assess the effect of tolcapone on levodopa dosage in parkinsonian patients whose "wearing-off" phenomenon has been controlled with more frequent levodopa dosage. After a 1-week placebo run-in, 97 patients were assigned randomly to receive placebo or tolcapo

Sulpiride in negative schizophrenia: A p
Sulpiride in negative schizophrenia: A placebo-controlled double-blind assessment
โœ S. D. Soni; A. Mallik; A. A. Schiff ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 505 KB

Twenty-four chronic schizophrenic long-stay hospital patients were identified, who had not received neuroleptic drugs for 8-30 (average 8 months) and met or exceeded a minimum criterion of severity of negative symptoms. They were randomly allocated to either sulpiride 200 mg twice daily or matching